367 results about "TG - Triglyceride" patented technology

A synergistic composition for improving the bioaccessibility of minerals comprises lutein, a casein phosphopeptide, or a 1, 3-dioleoyl-2-palmitic acid triglyceride, preferably in combination with one or more non-digestible oligosaccharides. These compositions are useful for the prevention and / or treatment of mineral deficiency and related conditions, preferably anemia, said minerals comprising iron and / or calcium.

Described are RNAi agents, compositions that include RNAi agents, and methods for dual inhibition of an Apolipoprotein C-III (APOC3) and Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene. The APOC3-PCSK9 RNAi agents disclosed herein inhibit the expression of an APOC3 and a PCSK9 gene. Pharmaceutical compositions that include one or more APOC3-PCSK9 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described TSLP RNAi agents to hepatic cells, in vivo, provides for inhibition of APOC3 and / or PCSK9 gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including hypertriglyceridemia and hypercholesterolemia.

The invention relates to an application of an Sdccag3 gene in preparation of a weight-reducing medicine for regulating glucose and lipid metabolism. The Sdccag3 gene is used as an action target to be applied to preparation or screening of the weight-reducing medicine for regulating glucose and lipid metabolism, and the nucleotide sequence of the Sdccag3 gene is as shown in SEQ ID No. 1. According to the application disclosed by the invention, the specific overexpressed Sdccag3 in adipose tissues in a mouse body can obviously inhibit the increase of the blood fat level, and the overexpressed Sdccag3 can also obviously improve the poor glucose tolerance, improve the insulin sensitivity, reduce the levels of serum triglyceride, cholesterol and low-density lipoprotein cholesterol of an obese mouse, improve the poor glucose tolerance and improve the insulin sensitivity. The insulin sensitivity is improved, obesity-related glycolipid metabolism is effectively regulated and controlled, the effect of reducing blood lipid and blood sugar is achieved, and the compound can be used for preparing weight-losing drugs for reducing blood lipid and blood sugar.

The invention discloses a horse milk-derived small molecule peptide, the amino acid sequence of which is Met-Ser-Pro-Phe (MSPF), and the molecular weight of which is 480.571 Da. The small molecule peptide disclosed by the invention has the activity of inhibiting pancreatic lipase (PL), the inhibition rate on the pancreatic lipase is 61.44%, and the accumulation of the content of triglyceride (TG) in oleic acid-induced human liver cancer (HepG2) cells can be reduced, so that the small molecule peptide can be used for inhibiting the pancreatic lipase (PL). The small molecule peptide can be applied to preparation of preparations for treating or assisting in treating hyperlipidemia and obese people, is simple to prepare, and is suitable for industrial production and market popularization and application.

The invention relates to the technical field of genetic engineering, in particular to a recombinant vector, an expression plasmid, a recombinant schizochytrium limacinum mutant and a method for increasing the DHA content of microorganisms. The LIP1 gene for coding lipase in the microbial lipid droplet protein is knocked out through a homologous recombination technology, and the production of lipase in the microbial lipid droplet can be effectively inhibited, so that the hydrolysis process of triglyceride of polyunsaturated fatty acid stored in the lipid droplet to glycerol and free fatty acid in the later stage of microbial culture is blocked, and DHA is prevented from being lost from a TAG repository; experimental verification shows that in microorganisms represented by schizochytrium limacinum, the DHA content can be increased by 21.8% compared with that of a wild type, the yield and purity of DHA are increased, the stability of the microbial fermentation process is guaranteed, and application and popularization are facilitated.

The invention relates to a diacylglycerol acyltransferase capable of synthesizing triglyceride as well as a coding gene and application of the diacylglycerol acyltransferase, and belongs to the field of enzymology, the nucleotide sequence of the gene for coding the diacylglycerol acyltransferase is as shown in SEQ ID NO.1, and the amino acid sequence of the diacylglycerol acyltransferase is as shown in SEQ ID NO.2. The invention also provides a recombinant plasmid and a recombinant engineering bacterium containing the gene of the enzyme. Diglyceride and an acyl donor are used as substrates, and triglyceride is catalytically synthesized through an acyl transfer reaction by using the enzyme. The invention provides an efficient tool for realizing enzymatic biosynthesis and large-scale production of natural triglyceride.

The invention discloses an immobilized enzyme reactor for preparing low-carbon-chain triglyceride, and relates to the technical field of bioreactors, the immobilized enzyme reactor comprises a reactor body, a bearing ball carrying enzyme, a feeding pipe, a discharging pipe, a conveying channel, a conveying mechanism and a collector; a filter pipe is arranged in the reactor body, the upper end of the filter pipe is communicated with the conveying channel through a feeding pipe, the lower end of the filter pipe is communicated with a collector through a discharging pipe, and the lower end of the collector is communicated with the conveying channel; unused bearing balls are contained in the collector, when the immobilized enzyme needs to be recycled, the vibrator on the filter pipe vibrates the filter pipe, the bearing balls in the filter pipe roll into the collector from the discharging pipe under the combined action of vibration and gravity, and the unused bearing balls in the collector are moved to the feeding pipe through the conveying mechanism and finally enter the filter pipe; an operator can open the cover plate of the collector and take out the used bearing balls from the discharge port, so that the effect of recycling the immobilized enzyme is realized.

A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.

The invention discloses application of an overexpressed carp lpla gene in regulation and control of expression of cyprinid fish tissue-related genes, and relates to the field of gene engineering, in particular to application of the overexpressed carp lpla gene in regulation and control of cyprinid fish tissue-related genes. The overexpressed carp lpla gene is applied to regulation and control of contents of lipid indexes of total cholesterol TC and triglyceride TG of different tissues of cyprinid fishes. The invention further discloses application of the overexpressed carp lpla gene in regulation and control of fat marker genes lpla, ppar gamma, Fabp3, fast and acaca of livers and muscle tissues of cyprinid fishes. The invention further discloses application of the overexpressed carp lpla gene in regulating and controlling the relative expression quantity of carp liver cell fat metabolism related genes lpla, ppar gamma, Fabp3, fast, acaca, hsl and pnpla2. The overexpressed carp lpla gene can regulate and control lipid deposition in different tissues in zebra fish, and a research model is provided for lpla to regulate and control fat deposition and differentiation. According to the overexpressed carp lpla gene disclosed by the invention, lpla high-expression carp hepatocytes are obtained through a liposome transfection technology, so that fat key gene expression in the carp hepatocytes is changed.

The invention discloses a model for predicting the progression hepatic fibrosis risk of a WD long-term maintenance treatment patient and a design method thereof, and relates to the technical field of medical information, the prediction model comprises the following steps: an input module receives patient parameter indexes composed of sex (SEX), platelet (PLT), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo-A1), laminin (LN) and copper cyanin (CER), and the input module receives the patient parameter indexes composed of sex (SEX), platelet (PLT), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo-A1), laminin (LN) and copper cyanin (CER); the processing module obtains single scores corresponding to the seven independent risk factors, the single scores are added to obtain a total score, the prediction probability corresponding to the total score is the risk of the progression-stage hepatic fibrosis of the WD long-term maintenance treatment patient, and the prediction risk probability is output through the output module. The column diagram prediction model established by the invention has relatively high accuracy, and can be conveniently used for early recognition and risk prediction of progression-stage hepatic fibrosis of WD long-term maintenance treatment patients.

The invention provides a method for preparing alpha-olefin from a triglyceride compound, and relates to the technical field of organic synthesis. According to the method provided by the invention, in a solvent environment, a hydrogen-containing atmosphere and at 50-300 DEG C, a triglyceride compound I reacts under the catalysis of a NiCu bimetallic catalyst to generate alpha-olefin II-1, alpha-olefin II-2 and alpha-olefin II-3. According to the method provided by the invention, the triglyceride compound is adopted as a reaction substrate, the alpha-olefin compound can be efficiently synthesized, the reaction is green and efficient, the atom utilization rate is high, and no pollution is caused.

The invention discloses a composition containing achillea millefolium extract, which is prepared from the following ingredients in percentage by weight: 45 to 55 percent of glycerol, 4 to 6 percent of hydrogenated lecithin, 3 to 5 percent of caprylic / capric triglyceride, 1 to 3 percent of 1, 2-hexanediol, 0.8 to 1.2 percent of achillea millefolium extract, 0.4 to 0.6 percent of ergothioneine and the balance of water. Through precise compounding of the achillea millefolium extract and the ergothioneine, the dual effects of anti-inflammation and skin repair are achieved, flavonoid and organic acid components in the achillea millefolium extract can effectively inhibit release of inflammatory mediators such as IL-6 and TNF-alpha, and sensitive symptoms such as red and swollen and pruritus are relieved.

The invention provides a composition for promoting differentiation of intestinal immune cells as well as a preparation method and application of the composition. According to the composition, 1, 3-dioleic acid-2-palmitic acid triglyceride and breast milk oligosaccharide are used in a combined manner, so that monocytes can be effectively promoted to differentiate into intestinal macrophages, and inflammation is reduced to a certain extent. After the monocytes are differentiated into the intestinal macrophages, the intestinal immune homeostasis and intestinal microbiota inflammatory response can be regulated, so that the mucosal immune homeostasis and intestinal epithelial cell barrier function are maintained. Therefore, the composition provided by the invention can improve the intestinal immune barrier by promoting the monocytes to differentiate into the intestinal macrophages, and provides a new thought for improving the early intestinal barrier of infants through nutritional supplement.

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. The first non-statin lipid lowering agent is an agent that inhibits cholesterol uptake (e.g. ezetimibe) and the second non-statin lipid-lowering agent is an inhibitor of microsomal triglyceride transfer protein (e.g. lomitapide). The combination therapy is useful in treating hypercholesterolemia, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

The invention provides a liquid crystal bionic water-locking and oxygen-permeating nursing composition as well as a preparation method and application thereof, and belongs to the technical field of cosmetics. The skin care product is prepared from components in percentage by weight as follows: 20%-40% of glycerin, 5%-10% of hydrogenated lecithin, 5%-10% of phytosterols, 0.1%-0.5% of sodium stearoyl glutamate, 0.01%-0.05% of sodium methyl stearoyl taurate, 0.1%-1% of ceramide NP, 1%-10% of caprylic / capric triglyceride, 1%-10% of squalane, 0.1%-1% of tocopheryl acetate, 0.01%-0.3% of DNA sodium, 0.001%-0.1% of fibronectin and the balance of water. 0.001-0.1% of soluble collagen and the balance of water. The liquid crystal bionic water-locking and oxygen-permeating nursing composition provided by the invention can better form a breathable protective film on the surface of skin, reduce water loss of the skin and help to repair a damaged skin barrier, so that the water-locking and oxygen-permeating nursing effect is achieved.

The invention relates to N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid or a pharmaceutical composition and application thereof, and relates to the technical field of biological medicines. According to the application disclosed by the invention, the N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid is found to have the effects of reducing total cholesterol, triglyceride and low-density lipoprotein cholesterol in serum and increasing high-density lipoprotein cholesterol in serum for the first time; the compound can be used for preparing a medicine for reducing total cholesterol in serum, a medicine for reducing triglyceride in serum, a medicine for reducing low-density lipoprotein cholesterol in serum and a medicine for increasing high-density lipoprotein cholesterol in serum, and can be used for preparing medicines for reducing total cholesterol in serum, triglyceride in serum, low-density lipoprotein cholesterol in serum and high-density lipoprotein cholesterol in serum. And an effective new means and a new way are provided for preparing the medicine for preventing or treating the hyperlipemia.

The invention relates to an shRNA (short hairpin Ribonucleic Acid) interference sequence of a targeted silence PCSK9 gene and a construction method and lipid-lowering application of a recombinant adeno-associated virus vector of the shRNA interference sequence. Hyperlipidaemia is a metabolic disease characterized by abnormal rising of cholesterol and triglyceride levels in blood, and the design of lipid-lowering drugs is the focus of attention to improvement of hyperlipidaemia. Proprotein convertase subtilisin / kexin type 9 (PCSK9) can be combined with a low-density lipoprotein receptor (LDL-R) and degrade the LDL-R, so that accumulation of LDL-C in blood is further promoted, and hyperlipidemia is caused. Aiming at the key target PCSK9, a specific shRNA interference sequence is designed, and a recombinant adeno-associated virus vector (rAAV) carrying the sequence is constructed by an enzyme digestion-connection method. In-vitro experiments prove that the vector can remarkably reduce the expression level of PCSK9 protein, so that the cyclic utilization of a low-density lipoprotein receptor (LDL-R) is promoted, and the concentration of low-density lipoprotein cholesterol (LDL-C) in plasma is reduced. The rAAV vector provided by the invention has the characteristics of low production cost, high transfection efficiency, lasting action time and the like, and provides a new thought for gene therapy of hyperlipidemia.

A use of a nutritional composition in promoting the bidirectional development of the gut and brain via the gut-brain axis. The nutritional composition comprises the following essential components: docosahexaenoic acid, eicosatetraenoic acid, galactooligosaccharide, 1,3-dioleic acid-2-palmitic acid triglyceride, lutein, nucleotide, lactoferrin, casein phosphopeptide, and probiotics. By combining and strengthening multiple functional active components, the gut health and brain cognitive development of the organism can be bidirectionally promoted by means of the microbiota-gut-brain axis. In particular, the present application can promote the regulation of flora in the gut of the organism, increase the abundance of beneficial bacteria, and decrease the abundance of harmful bacteria related to brain development diseases. The content of butyric acid in the gut can be increased, and the contents of acetic acid and propionic acid are decreased to promote brain and cognitive development.

The invention relates to a molecular target capable of specifically reducing cholesterol level without interfering triglyceride metabolism and application of the molecular target. The molecular target is the C terminal of ANGPTL3 protein. The invention also relates to an application of the inhibitor of the C terminal of the targeted ANGPLT3 protein (Angiopoietin-like3, angiopoietin-like protein 3) in preparation of a medicine, and the medicine is used for treating hypercholesteremia, atherosclerosis and coronary heart disease, and also relates to an application of the inhibitor of the C terminal of the targeted ANGPLT3 protein (Angiopoietin-like protein 3) in preparation of the medicine.

The present invention relates to triglyceride analogs labeled with radioisotopes, or salts thereof, for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) imaging. In addition, the present invention relates to compositions comprising the radiolabeled triglyceride analog, or a salt thereof, and methods for preparing the same. Further, methods of imaging using the radiolabeled triglyceride analog and uses of the radiolabeled triglyceride analog are disclosed herein. The invention also relates to an intermediate triglyceride analog for synthesis of the radiolabeled triglyceride analog.

A formulation comprising: at least one isocyanate compound; at least one bio-oil-based compound selected from the group consisting of triglyceride (TG)-based bio-oil compounds and esterified bio-based fatty acid compounds; optionally, a catalyst compound for promoting urea / polyurethane formation; the ratio of the TG-based bio-oil compound to the esterified fatty acid compound is from 60 / 40 to 0 / 100, preferably from 55 / 45 to 0 / 100, more preferably from 50 / 50 to 40 / 60, most preferably from 45 / 55 to 50 / 50, and the at least one isocyanate compound (a) is present in an amount of at least 90 wt%, based on 100 wt% of the total formulation.

The application discloses a method for detecting triglyceride positional isomers, which comprises the following steps: providing a triglyceride sample to be detected; mixing the triglyceride sample with a salt compound to obtain a to-be-detected liquid; detecting the to-be-detected liquid by using a high-resolution mass spectrometer so as to obtain a primary mass spectrum result and a secondary mass spectrum result; and obtaining the structure type of each branched chain of the triglyceride sample based on the primary mass spectrum result and the secondary mass spectrum result, wherein the triglyceride sample contains three fatty acid chains in sequence, namely sn1, sn2 and sn3, and the structure type of the triglyceride sample comprises AAA type, AAB type, ABA type and ABC type according to the structure difference of the sn1, sn2 and sn3. The method obtains the primary and secondary mass spectrum fragment modes of rich information by using the high-resolution mass spectrometer, the fine cleavage rule of the TGA positional isomer, and a comprehensive characterization strategy of the sn positional isomer of the TGA is constructed.

The present invention relates to a visual detection method and a detection kit for lipase based on changes in liquid viscosity. The lipase detection method provided by the present invention generates a hydrogel after ions intervene in the reaction system to cause phase separation. Due to different viscosities and water contents in the supernatant, different flow distances are presented on the paper base; the flow distance on the paper base can be measured to achieve quantitative detection of the object to be detected. In addition, the invention relates to a paper-based biosensing method for detecting enzymes due to viscosity changes caused by phase separation, taking lipase as an example. The present invention combines sodium alginate and calcium ion cross-linking gelation, enzymatic hydrolysis reaction, phase separation to cause viscosity changes, and a detection method combined with a paper base to design a convenient, simple and sensitive sensing method. Taking lipase as an example, a two-step reaction of sodium alginate and calcium ions, triglycerides and lipase is combined to design a lipase paper-based detection method with high sensitivity, good specificity and simple operation, which has the potential for commercial detection.

The invention discloses application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period, belongs to the technical field of feed additives, and particularly relates to application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period. It is found that paeonol can significantly reduce the activity of glutamic-pyruvic transaminase in the liver, significantly reduce the content of cholesterol and the content of triglyceride in serum, significantly reduce hepatic cell fatty degeneration and lipid droplet aggregation in a hepatic tissue pathological section, relieve liver injury and lipid metabolism disorder, and significantly improve the liver function. The paeonol can effectively improve the fatty liver hemorrhagic syndrome of the laying hens in the later egg laying period, and the paeonol can recover the storage capacity of ovary by improving the survival rate of follicles, improve the egg laying performance of the laying hens and improve the egg laying rate.

Methods improve cognitive functioning, for example, at least one of episodic memory, executive function, or language skills; supporting memory and / or recall; providing energy and / or ketones to the brain; and / or preventing and / or treating mild cognitive impairment (MCI) in an individual. A composition comprising medium chain triglycerides (MCTs) can be administered to the individual in a daily dosage providing from about 15 g to about 45 g MCTs. The MCTs can include from about 51 wt % to about 90 wt % of octanoic acid. The daily dose can be provided in at least two servings, for example, 2 or 3 servings. Each serving can provide about 15 g MCTs and can include octanoic acid and decanoic acid in a weight ratio of, for example, about 60:about 40. The individual can be 65 years or older and / or have mild cognitive impairment (MCI).

The present invention relates to a combination of Chinese and Western medicines for treating hyperlipidemia. In particular, the present invention relates to a pharmaceutical combination of probucol and red yeast rice, a pharmaceutical composition or a kit comprising probucol and red yeast rice, and the use of the pharmaceutical combination, pharmaceutical composition or kit in preparing a medicament for treating hyperlipidemia, particularly severe hypertriglyceridemia and severe hypercholesterolemia. The present invention is characterized in that the pharmaceutical combination, pharmaceutical composition or kit comprising probucol and red yeast rice comprises a small dose of probucol and red yeast rice, and the probucol and red yeast rice are configured for simultaneous administration.

The invention relates to euphausia superba-derived diacylglycerol acyltransferase as well as a coding gene and application thereof, and belongs to the field of enzymology, the nucleotide sequence of the gene for coding the enzyme is as shown in SEQ ID NO.1, and the amino acid sequence of the enzyme is as shown in SEQ ID NO.2. The invention further discloses a preparation method of the euphausia superba-derived diacylglycerol acyltransferase. The invention also provides a recombinant plasmid and a recombinant engineering bacterium containing the gene of the enzyme. Diglyceride and an acyl donor are used as substrates, and triglyceride is catalytically synthesized through an acyl transfer reaction by using the enzyme. The invention provides an efficient tool for realizing enzymatic biosynthesis and large-scale production of natural triglyceride.

Provided are a method of assisting the detection of nonalcoholic steatohepatitis (NASH) and a method that is able to assist in determining the degree of progression of any condition associated with NASH, which are far less invasive than liver biopsy and include simple operations and are independent of the skills of technicians.The present invention provides a method of assisting the detection of nonalcoholic steatohepatitis, including measuring the abundance of LDL-TG and / or ApoE-rich HDL-C contained in a test blood sample isolated from a living body. Also, the present invention provides a method of assisting in determining the degree of progression of at least one medical condition associated with nonalcoholic steatohepatitis, which medical condition(s) is(are) selected from the group consisting of fatty degeneration (steatosis), inflammation, ballooning degeneration, and fibrosis, including measuring the abundance of LDL-TG and / or ApoE-rich HDL-C contained in a test blood sample isolated from a living body.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.